Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Cancer (Pilot Study)

NAEnrolling by invitationINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 4, 2025

Primary Completion Date

April 4, 2027

Study Completion Date

April 4, 2027

Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
PROCEDURE

Selective plasma adsorption of extracellular DNA

Selective plasma adsorption of extracellular DNA using NucleoCor® sorption columns (Pocard Ltd., Russia) on the Spectra Optia™ Apheresis System (Terumo Blood and Cell Technologies, USA). NucleoCor® is a sorption column for plasma adsorption containing porous spherical agarose beads with a ligand that selectively binds extracellular DNA. This medical device has a Registration Certificate No. РЗН 2022/18982 in Russian Federation. Participants will receive selective plasma adsorption of extracellular DNA twice: once during the tumor removal surgery (the procedure will be initiated at the time of pancreatic tumor mobilization and will be stopped an hour after removal of the organ complex) and once on the day after the surgery.

Trial Locations (1)

143421

Ilyinskaya Hospital, JSC, Moscow

All Listed Sponsors
collaborator

POCARD Ltd.

UNKNOWN

collaborator

University Clinic of Lomonosov Moscow University

UNKNOWN

lead

Ilyinskaya Hospital, JSC

OTHER